Jim Simons's position in Prelude Therapeutics is currently worth $1.15M. That's 0.00% of their equity portfolio (2106th largest holding). The first Prelude Therapeutics trade was made in Q4 2021. Since then Jim Simons bought shares nine more times and sold shares on nine occasions. The investor's estimated purchase price is $1.28M, resulting in a loss of 10%.